TNF Pharmaceuticals Stock Soars 6.11% Despite 10-K Filing Delay

TNF Pharmaceuticals' stock surged 6.11% in pre-market trading on April 2, 2025, reflecting a significant uptick in investor interest and confidence in the company's prospects.

TNF Pharmaceuticals, a clinical-stage pharmaceutical company, has been making strides in developing novel therapeutic platforms. The company's MYMD-1 drug platform, which regulates the immune system to control TNF-a and other pro-inflammatory cytokines, is being developed to treat autoimmune diseases and delay aging. Additionally, the Supera-CBD platform aims to address chronic pain, addiction, and epilepsy, leveraging a synthetic derivative of cannabidiol (CBD).

Recently, TNF Pharmaceuticals announced a delay in filing its Annual Report on Form 10-K for the financial period ending December 31, 2024. This delay could be attributed to various factors, including the need for additional time to finalize financial statements or address regulatory requirements. Despite this setback, the company's focus on innovative therapeutic solutions continues to drive investor optimism.